.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
UBS
Federal Trade Commission
Harvard Business School
Julphar
Chinese Patent Office
McKinsey
Moodys
Covington
Farmers Insurance

Generated: November 20, 2017

DrugPatentWatch Database Preview

EGRIFTA Drug Profile

« Back to Dashboard

What is the patent landscape for Egrifta, and what generic Egrifta alternatives are available?

Egrifta is a drug marketed by Theratechnologies and is included in one NDA. There are three patents protecting this drug.

This drug has forty-four patent family members in sixteen countries.

The generic ingredient in EGRIFTA is tesamorelin acetate. Two suppliers are listed for this compound. Additional details are available on the tesamorelin acetate profile page.

Summary for EGRIFTA

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 9
Drug Prices:see details
DailyMed Link:EGRIFTA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EGRIFTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010► Subscribe► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EGRIFTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,939,386 Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency► Subscribe
6,696,063 Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy► Subscribe
8,314,066GH secretagogues and uses thereof► Subscribe
8,481,489GH secretagogues and uses thereof► Subscribe
8,435,945GH secretagogues and uses thereof► Subscribe
6,458,764 GRF analogs with increased biological potency► Subscribe
6,020,311 GRF analogs with increased biological potency► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EGRIFTA

Country Document Number Estimated Expiration
Spain2164626► Subscribe
Japan3576170► Subscribe
Australia697119► Subscribe
Mexico2007004682► Subscribe
Spain2163020► Subscribe
Australia5500799► Subscribe
Australia2010200224► Subscribe
World Intellectual Property Organization (WIPO)2004105789► Subscribe
South Korea101228229► Subscribe
World Intellectual Property Organization (WIPO)9637514► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Covington
McKesson
Fish and Richardson
Deloitte
Accenture
Boehringer Ingelheim
McKinsey
Julphar
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot